• 1.

    Perkovic V, et al. Management of patients with diabetes and CKD: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2016; 90:11751183.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41:26692701.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    de Boer IH. The expanding resume of SGLT2 inhibitors. Lancet Diabetes Endocrinol 2019; 7:585587.

  • 4.

    Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306.

  • 5.

    Tuttle KR. SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease. Lancet Diabetes Endocrinol 2019; 7:414415.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    American Diabetes Association. 7. Diabetes Technology: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42 [Suppl 1]:S71–S80.

    • Search Google Scholar
    • Export Citation

Diabetes and CKD: New Approaches to Managing a Common Condition

  • 1 Ian H. de Boer, MD, MS, is Professor of Medicine in the Division of Nephrology and Associate Director of the Kidney Research Institute at the University of Washington, Seattle, USA.
Restricted access
Save